TM Owner ImmunoGen / AbbVie
Mirvetuximab Soravtansine IV 100mg Vial
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Mirvetuximab Soravtansine IV, sold in the US under the brand name Elahere (mirvetuximab soravtansine-gynx), is an antibody-drug conjugate combining a folate receptor alpha (FRα)-targeted antibody with the cytotoxic agent DM4.
- It is approved for adults with FRα-positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have already received one to three prior lines of systemic therapy.
- Before treatment, tumour tissue must be tested with an FDA-approved companion diagnostic to confirm FRα expression; patients who do not test positive are not candidates.
- Elahere is given by intravenous infusion only, once every three weeks, at a specialist oncology facility under the supervision of a clinician experienced in cancer chemotherapy; it is never self-administered.
- There is no separate EU-approved brand or indication identified at this time; this content is based on the US label.
Side Effects
- Very common side effects (occurring in 20% or more of patients) include raised liver enzymes, fatigue, blurred vision, nausea, diarrhoea, abdominal pain, keratopathy (corneal changes), nerve pain or numbness (peripheral neuropathy), muscle or joint pain, dry eye, low blood counts, constipation, vomiting, and reduced appetite.
- Elahere carries a boxed warning for ocular toxicity: eye problems including blurred vision, keratopathy, dry eye, sensitivity to light, eye pain, and uveitis occurred in 59% of patients, with severe (Grade 3) reactions in about 11%.
- Report any change in vision, eye pain, redness, or light sensitivity immediately, as treatment may need to be paused, dose-reduced, or stopped.
- Also report new or worsening cough, shortness of breath, or fever, which can signal lung inflammation (pneumonitis).
- Patients must have an eye examination before starting treatment and periodically during therapy, and use the prescribed lubricating eye drops and corticosteroid eye drops as directed.
Precautions & Warnings
- Because of the risk of severe ocular toxicity, Elahere requires an ophthalmologic examination before the first dose and again before alternating cycles for the first eight cycles, with prophylactic lubricating eye drops used throughout treatment; corticosteroid eye drops, dose interruption, dose reduction, or permanent discontinuation may be required depending on severity.
- Contact lenses should generally be avoided unless a specialist advises otherwise.
- Elahere can cause pneumonitis (lung inflammation), so any new respiratory symptoms must be reported promptly.
- Based on its mechanism, Elahere can cause fetal harm; females of reproductive potential should use effective contraception during treatment and for 7 months after the final dose, and males with partners of reproductive potential should use contraception for 4 months after the last dose.
- Do not breastfeed during treatment and for 1 month afterward.
- Liver function and blood counts are monitored regularly during treatment; peripheral neuropathy should also be monitored and may require dose adjustment.
Avoid Interactions
- Tell the treating oncology team about every medicine, herbal product, and supplement being used, since Elahere is combined with other cancer treatments only under specialist supervision.
- Strong CYP3A4 inhibitor drugs, such as certain antifungal or antibiotic medicines, can increase exposure to the DM4 component released from Elahere and raise the risk of side effects; if a strong CYP3A4 inhibitor must be used at the same time, patients are monitored more closely for adverse reactions.
- Elahere must be diluted only in 5% dextrose solution before infusion; it is physically incompatible with normal saline (0.9% sodium chloride) and must not be mixed or co-infused with it or with other medicines through the same line.
- As with other chemotherapy-type agents, combining Elahere with other drugs that affect the eyes, lungs, or bone marrow should be discussed with the treating team so that side effects can be monitored closely and reported at once if they occur.
References
Frequently Asked Questions
Elahere (mirvetuximab soravtansine-gynx) treats adults with FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer after 1 to 3 prior treatment regimens. A companion diagnostic test must first confirm FRα-positive status. It combines a folate-receptor-targeted antibody with a cell-killing chemotherapy component.
Elahere is given as an intravenous infusion at a cancer clinic once every 3 weeks, at a dose based on your weight. The first infusion is given slowly and the rate is increased if it is well tolerated. You cannot give it to yourself.
Elahere's boxed warning is for eye (ocular) toxicity: blurred vision, dry eye, eye pain, light sensitivity, and keratopathy affect over half of patients. Report any vision change immediately. Other common effects include fatigue, nausea, diarrhoea, and nerve tingling or numbness.
Avoid strong CYP3A4 inhibitor medicines unless your oncologist approves them, since they can raise Elahere's toxicity. Avoid contact lenses unless your eye doctor says it is safe, and use your prescribed eye drops exactly as directed throughout treatment.
You will have blood tests and an eye check at scheduled visits, including before every other cycle for the first 8 cycles. The infusion itself takes about 30 minutes to start, given more slowly at first, then faster if you tolerate it well.
Elahere can harm an unborn baby, so effective contraception is needed during treatment and for 7 months after the last dose (4 months for male partners). Treatment continues in 3-week cycles for as long as it is working and side effects are manageable.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
